AtomVie Celebrates Grand Opening of State-of-the-Art Radiopharmaceutical Facility in Hamilton
AtomVie Marks a New Era in Radiopharmaceutical Manufacturing
On September 5, 2026, AtomVie Global Radiopharma celebrated the grand opening of a remarkable new manufacturing facility in Hamilton, Ontario. This state-of-the-art site is strategically designed to address the burgeoning demand in the radiopharmaceutical sector. With an investment exceeding $160 million, the facility spans over 72,300 square feet and is hailed as the largest single-site Contract Development and Manufacturing Organization (CDMO) in North America dedicated to the development of radiopharmaceuticals.
The newly established facility amplifies AtomVie’s production capabilities more than tenfold, enabling both low and high-volume productions. It is meticulously engineered to facilitate a seamless transition from the initial stages of development to commercial manufacturing, offering adaptable spaces that meet future client requirements. This significant milestone not only elevates AtomVie’s operational capacity but also enhances its ability to deliver precision therapies that can change patients’ lives globally.
Background of AtomVie
Founded as a spinoff from the Centre for Probe Development and Commercialization (CPDC) at McMaster University, AtomVie was established to position Canada as a leader in the innovation and manufacturing of radiopharmaceuticals. Over the years, AtomVie has successfully developed a robust team of highly skilled professionals and plans to grow its workforce to over 200 employees by the end of 2026.
The company has a proven track record, supporting more than 70 clinical development programs and technology transfers, producing over 1,000 batches under cGMP standards, and supplying more than 4,400 cGMP doses to patients across 28 countries and six continents. Impressively, AtomVie boasts a delivery success rate exceeding 99%, thanks to its commitment to quality.
Significance of the Grand Opening
During the grand opening event, dignitaries, clients, partners, and community members toured the facility, gaining insights into how AtomVie’s expertise is shaping the future of nuclear medicine. Bruno Paquin, the CEO of AtomVie, expressed pride in this accomplishment, stating, "This grand opening marks the next chapter in AtomVie’s journey and stands as a testament to Canadian innovation in nuclear medicine." He emphasized the importance of the new facility, noting that it enhances AtomVie’s reliability in all aspects of drug supply and supports the development and commercialization of product portfolios for its partners.
Commitment to Global Health
Kevin McNeill, AtomVie’s Chairman, noted, "The inauguration of our new facility is a reflection of our team's discipline and dedication, as well as the confidence from partners supporting our growth." He affirmed that the new site establishes AtomVie as a leading CDMO in radiopharmaceuticals, ready to meet the commercial scale demands of the industry.
This facility will not only help in the production of life-saving therapies but also in addressing the increasing global demand for targeted treatments. As AtomVie embarks on this new venture, it reinforces its mission of transforming patient lives through the supply of high-quality radiopharmaceuticals worldwide.
About AtomVie Global Radiopharma
AtomVie is a leading global CDMO that provides a comprehensive range of scientific, technical, regulatory, logistical, and quality services, combined with specialized infrastructure for radiopharmaceutical development, from Phase I to III clinical studies to commercialization. For more information about AtomVie and its innovative solutions, please visit AtomVie Official Website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.